Continuous flow manufacturing process of 1,4-dithiothreitol to meet its increasing demand for disease test kits.

1,4-二硫苏糖醇的连续流程生产工艺，以满足其对疾病检测试剂盒日益增长的需求。

• 批准号: 562465-2021
• 负责人: Charette, André
• 金额: $ 3.17万
• 依托单位: Université de Montréal
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=722100
• 关键词: Continuous; flow; manufacturing; process; dithiothreitol

The partnership between BioVectra Inc. and Prof. André B. Charette-Université de Montréal is a milestone towards an in-house Canadian manufacturing of high quality compounds in order to meet an increasing Canadian market demand. This approach will allow to mitigate Canada's heavy reliance on foreign suppliers and hence empower the Canadian economy and health care system. Specifically, the goal of this partnership is to develop an efficient synthetic route under continuous flow conditions to manufacture and supply on demand 1,4-dithiothreitol (DTT) to meet the rapidly expanding needs of the global and Canadian market. This reagent is routinely used as a key component in assays and in particular in COVID-19 testing kits where the demand has increased exponentially in the last year. The optimal synthetic procedure using continuous flow techniques will be develop within the Center for Continuous Flow Synthesis (CCFS), a state of the art laboratory located at Université de Montréal. The optimized process will then be effectively transfer to BioVectra's continuous flow large scale manufacturing facility for mass production and market distribution of DTT. This partnership is a turn-key solution to rapidly, safely and effectively supply the Canadian market with the crucially needed DTT. Through this partnership, trainees will gain experience in solving real world problems and well thought after pluri-disciplinary knowledge that will promote their successful entrance in the work force.

BioVectra Inc.安德烈教授B。蒙特利尔夏雷特大学是加拿大内部制造高品质化合物的一个里程碑，以满足不断增长的加拿大市场需求。这种做法将有助于减轻加拿大对外国供应商的严重依赖，从而增强加拿大经济和医疗保健系统的能力。具体而言，该合作伙伴关系的目标是在连续流动条件下开发一种高效的合成路线，以按需生产和供应1，4-二硫苏糖醇（DTT），以满足全球和加拿大市场快速增长的需求。该试剂通常用作检测试剂盒的关键成分，尤其是COVID-19检测试剂盒，去年其需求呈指数级增长。使用连续流技术的最佳合成程序将在连续流合成中心（CCFS）内开发，该中心是位于蒙特利尔大学的最先进实验室。优化后的工艺将有效地转移到BioVectra的连续流大规模生产设施，用于DTT的大规模生产和市场分销。这一合作伙伴关系是一个交钥匙解决方案，可以快速，安全，有效地为加拿大市场提供急需的DTT。通过这种伙伴关系，受训者将获得解决真实的世界问题的经验，并在多学科知识之后获得良好的思考，这将促进他们成功进入劳动力市场。